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Diet is an important factor in gastrointestinal health. A synbiotic food option
utilizing prebiotic and probiotic ingredients may be beneficial for improving
gastrointestinal health. To conduct a human subject study of synbiotic ice cream
containing prebiotic (inulin) and two strains of probiotics (Lactobacillus casei KE99 and
Bifidobacterium bifidum) to determine its effectiveness as a carrier for a these
ingredients and to identify any negative gastrointestinal side effects.
The study started with baseline data collection including a food frequency, a three
day food recall, and one stool sample. The study was a 12 week crossover design with
three weeks consuming placebo or treatment ice cream then a three week washout period.
After, participants would switch to the other ice cream. Fecal samples were collected to
examine bacteria level changes. Participants kept a log book during the two treatment
periods to track gastrointestinal symptoms and record amount of ice cream consumed.
There was a not a significant difference in amount of ice cream consumed during
placebo and treatment periods; t(11)= 0.31, p = 0.98. Change in reported flatulence level
was not statistically significant; t(11)= -0.82, p = 0.43. There was no significant change
in number of stools per day between treatment and control; t(11)= -2.09, p = 0.06.
Change in Bristol scale values during placebo and treatment was not statistically

significant; t(11)= -0.71, p = 0.49.There was not significant difference in the
Bifidobacterium bifido values during treatment (M=47.13, SD=103.22) and control
(M=24.11, SD=80.29); t(12)= 1.72, p = 0.11. Synbiotic ice cream could be an effective
carrier for probiotics and prebiotics. Consumption did not cause an increase in
gastrointestinal symptoms. The results of the bacteria level change were not significant.
Further research is needed.
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CHAPTER 1
LITERATURE REVIEW
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Gastrointestinal Health
Gastrointestinal health is a very important part of overall health and can impact
quality of life. In the United States colon cancer is the third most common cancer, and the
risk of developing colon cancer is about one in 20, with nearly 50,000 deaths from colon
cancer in the last year (1, 2). Approximately 22% of the population have chronic
constipation, 5.6% have irritable bowel syndrome and over 2.2 million Americans have
been diagnosed with diverticular diseases. As many as one in 10 Americans over the age
of 40 have diverticulosis (3, 4). The health of the gastrointestinal tract is affected by
many factors. These include pH, competition for nutrients, host conditions, metabolic
interactions among bacteria and individual dietary intakes (5). Several of these factors are
hard to influence with outside treatments that are non-invasive, and it is difficult to
measure their effect. The main area that can be impacted with simple treatment is dietary
intake. Two main categories have been reported in research literature and have measured
the ability they have to improve gastrointestinal health. These are the consumption of
prebiotic food ingredients, sometimes called functional foods (e.g. fructooligofructoses)
and probiotic microorganisms such as Lactobacillus and Bifidobacterium).
Gastrointestinal Tract and the Gut Microbiota
The human gastrointestinal (GI) tract contains over 1014 microbial cells with more
than 1,000 different bacterial type (6). At birth, the GI tract is sterile. The GI tract is
initially colonized by facultative anaerobic bacteria. After these anaerobic bacteria
remove any trace of oxygen from the environment colonizing bacteria are determined by
the infant’s food sources. Breastfed infants receive a wide array of microbiota from their
mothers including strains of Bifidobacterium (7). Once at adulthood most bacteria in the
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guy are non-sporing anaerobes including Bifidobacterium spp. and Lactobacillus spp.
These microorganisms through fermentation break down substrates from diet such as
dietary fibers and endogenous secretions. Bacteria strains have differing metabolic
activities and fermentation end products which result in them being categorized as either
beneficial or potentially pathogenic. The benefits from having the good bacteria strains
are many. These benefits include: preventing GI tract disorders (including irritable bowel
disease), preventing metabolic syndrome, improving immune response, decreasing
lactose intolerance, reducing risk of getting antibiotic-associated diarrhea (especially
when caused by Clostridium difficile), and potentially decreasing risk of colon cancer (6,
8, 9). The type and diversity of the microbiota in GI tract is also an environmental factor
in obesity and the imbalance of the microbiota contribute to liver disease (8).
Probiotics
Research related to the gut microbiota has focused mainly on how it can be
improved through the addition of more of the beneficial bacteria. Supplements or foods
that contain these microorganisms are called probiotics. Probiotics are defined as live
microorganisms that confer a health benefit on the host when administered in adequate
amounts (9-11). Probiotic supplements can be found in a variety of forms including: pill,
powder, capsule, gummy, and chewable. Probiotics are also found naturally in certain
foods, or can be added to foods.
Taking probiotics can improve the immune response in several ways. Certain
probiotics work by inhibiting adhesion and displacing pathogens for instance, Esherichia
coli, Staphylococcus aureus, and Clostridium difficile which decreases risk of illness
(12). Studies have shown that taking probiotics during antibiotic treatment can be
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beneficial to maintaining healthy gut microbiome and decreasing the risk of experiencing
antibiotic-associated diarrhea (13). Probiotics supplements of Lactobacillus casei,
Lactobacillus reuteri, or Bifidobacterium animalis BB12 can be used when a patient
already has acute diarrhea to decrease duration of the illness. Probiotics can be used to as
treatment for someone with irritable bowel disease, ulcerative colitis, Crohn’s disease and
other GI disorders. Finally, probiotic usage has been linked to a decrease in serum
cholesterol. Due to the benefits that probiotics have on overall health, consuming
probiotics is a good choice when trying to improve overall health.
Research has been done analyzing probiotic supplements and food products for
bacterial content and label accuracy. The results of these studies showed that many
products have labels that are inaccurate with respect to the number of bacteria species and
type of bacteria species. A few examined products did not contain the bacteria species
listed, and some contained the same strain but were named differently. Some of these
studies reported supplements that did not contain viable bacteria (14-18). The safety and
functionality of these products is impacted by the label accuracy and as such it is
important to correctly identify not only the species but the strain of bacteria used (14).
Bifidobacterium
Bifidobacterium bifidum is a bacterial species of the bifidobacterium genus and is
one of the most common probiotic bacteria. This helpful bacteria can be found in
mammals, including humans. It is a gram-positive rod shaped bacteria that is non-motile,
anaerobic, and non-spore forming. It can be found living in clusters, pairs, or single units.
The majority of B.bifidum population is found in the colon and lower small intestine, but
it can also be found in breast milk and in the vagina. B.bifidum as part of the

12
gastrointestinal microflora helps the GI tract function better and reduces the chances of
acute diarrhea and can help E.coli infections. Increasing the quantity of B.bifidum in the
body can help boost immune function by decreasing the symptom severity and length of
time a person is infected with the common cold (10). This bacteria works in the GI tract
by breaking down both long and short chain simple sugars. Increasing B.bifidum in the GI
tract can be achieved in a few ways. This bacteria can be transmitted through breast milk
from the mother to the infant or it can be consumed in probiotic foods and supplements to
help improve B.bifidum counts within the gut microbiota.
In vitro studies demonstrated that fermentation and growth rates of bifidobacteria
increase when short chain oligofructose is the carbon source and that the chain length
affects the microflora composition and activity (19-22). Numerous human studies have
been conducted that demonstrate the effect of consumption of bifidobacteria on
increasing the colonic bifidobactera and subsequent return to baseline within days of
discontinued consumption of bifidobateria (23-25).
Lactobacillus
Lactobacillus paracasei subspecies paracasei is a heterofermentative lactic acid
bacteria. Like Bifidobacterium, it is also a gram-positive rod shaped bacteria. This
bacteria is commonly used in dairy product fermentation as well as probiotic
supplements. Like Bifidobacterium, it is found in the human GI tract and found in the
mouth. It is frequently used in commercial probiotic supplements or probiotic food
products because it survives transit through the gastrointestinal tract well and retains
functionality and viability well, especially in food products (26). L.Paracasei subs.
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Paracasei is a beneficial bacteria that is desirable to have as part of the human gut
microbiota.
Prebiotics
Numerous studies have focused on prebiotic ingredients as functional foods and
how they impart a positive impact on the health of the gastrointestinal tract (9, 27-29).
Prebiotics are defined as non-digestable food ingredients that positively affect the host by
selectively stimulating the growth and/or activity of beneficial bacterial species (such as
Bifidobacterium and Lactobacillus) in the colon, and thus improve host health (30). Nondigestable fructooligofructoses are prebiotic ingredients that have been shown to have
positive effect on host health, reducing the risk of gastrointestinal diseases such as
diverticulosis, diverticulitis and colon cancer (31-34). Consuming prebiotics does come
with a risk of certain side effects. The side effects from consuming prebiotics can result
in a higher level of flatulence and possible constipation and/or diarrhea. These side
effects usually last a short period of time while the body adjusts to the ingredient. Side
effects can vary depending on the type of prebiotic (27).
Fructooligofructoses are categorized by their degree of polymerization.
Fructooligofructoses that have a degree of polymerization from 2-10 are named
oligofructose (22, 35). Inulin is a generic term that covers all β (1←2) linear molecules
with a degree of polymerization (DP) varying from 2 to ~60 units (22, 25). Inulin, as a
type of fructooligofructose, acts as a growth substrate for gut microflora. The bacteria
that ferment the inulin gain the energy needed to grow and multiply (21, 33, 35). One
study found that inulin-type fructans with a longer DP have a better prebiotic effect. This
included inulin having a higher butyrate and propionate production and better stimulation
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of lactic acid-producing bacteria (such as Lactobacillus and Bifidobacterium) (36).
Fructooligofructoses are digested by certain types of bacteria including Bifidobacterium
and Lactobacillus. When Bifidobacteria is the predominant bacteria in the gut, such as
the case when fructooligofructoses are ingested in the adequate amounts, the number of
pathogenic bacteria such as E. coli and Clostridia are decreased by competitive inhibition
(22, 25, 32).
Bacteria ferment different varieties of fructooligofructoses at different speeds
(21). This variation is due mainly to the difference in chain lengths as the shorter chain
lengths can be broken down more quickly and the longer chains require a longer time.
This variation in speed may also be correlated to location of fermentation, with longer
chains being broken down in the more distal regions of the colon at a slower rate. These
longer chains due to the slower rate and more distal location could lead to less side
effects including less flatulence. A beneficial dose of 20g per day has been shown to be
effective in producing an increase in bifidobacteria, although considerable individual
variation existed (33).
Mixed findings have been reported for the consumption of inulin or oligofructoses
(33, 37-39). Results depend on the amount and type of fructooligofructose consumed,
length of time consumed, and wash out periods between treatments. Side effects
(abdominal pain, distention, flatulence, constipation or diarrhea) were dependent on these
same factors. Kruse, et al. concluded that long term inulin supplementation was useful
and can positively change bifidobacteria without major gastrointestinal discomfort (39).
A project conducted by Dr. Hutkins at University of Nebraska - Lincoln focuses
on assessing and enhancing stability of prebiotics in foods. In this project, the focus is on
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stability of oligosaccharides in food process; specifically heat processing (baking,
pasteurization and extrusion) (40).
A study was initiated by Mendlick to determine the effect of fructooligofructoses
of different chain lengths on gastrointestinal parameters (41, 42). Nineteen healthy
subjects aged 20-57 years old took part in a ten-week cross-over designed study. Subjects
consumed either inulin or oligofructose for three weeks followed by a two-week washout
period between treatments. Stool samples were collected five times (baseline, two
treatments, two washout) and analyzed for bifidobacteria. Daily records were kept for
stool frequency, stool consistency and flatulence frequency. Bifidobacteria counts
(CFU/ml) were higher (trending toward significance) during inulin and oligofructose
intakes and washout periods than baseline counts. Inulin and oligofructose treatment
periods had a significant effect on stool consistency (watery/very hard) and flatulence
frequency, but not stool frequency, when compared to baseline (P<0.05). Further research
is needed to confirm these results due to small sample size and the need for a longer
washout period between treatments.
A recent study was conducted to determine what effect inulin has on pre-diabetics
with regard to weight management and ectopic fat. It was an 18-week study broken into a
nine week weight loss phase and nine week weight maintenance phase. Their findings
showed that the inulin had two effects on diabetes risk. These effects were promoting
weight loss and reducing intrahepatocellular and intremyocellular lipids in the subjects
with prediabetes (43). This study illustrates that inulin could be beneficial for more than
just improving gut microflora.
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Synbiotics
Research has been conducted to examine what happens when probiotic bacteria
and prebiotics are supplemented together. These supplements and foods are categorized
as synbiotic since the probiotics and prebiotics work together synergistically to improve
gastrointestinal health (9). A study of similar design to Mendlick’s study was conducted
to determine the microbiological effects of consuming a synbiotic containing
Bifidobacterium bifidum, bifidobacterium lactis, and oligofructose in capsule form with
elderly persons (41, 42, 44). The study was a double-blind randomized controlled trial
with 18 participants and lasted for eight weeks consisting of three phases: a prefeeding
period (1 week), the feeding period (4 weeks), and a postfeeding/washout period (3
weeks). During the feeding phase, the synbiotic group received supplements of six g of
Raftilose Synergy1™ (combination of inulin and oligofructose) and a gelatin capsule
containing 100 mg of a Freeze-dried probiotic containing ∼3.5 × 1010 CFU each of B.
bifidum strain BB-02 and B. lactis BL-01 (Rhodia). The placebo group received six g of
maltooligosaccharides. All capsules were taken with a cold drink two times a day after
meals. Fecal samples from weeks 1, 3, 4, 5, 6, and 8 were collected and analyzed.
Throughout the feeding period both bifidobacteria species were detected in fecal samples
from all subjects in the synbiotic group. Of these, at least one species remained detectable
in fecal samples three weeks after feeding in subjects that had none of these species
present during the control week. The results indicated that synbiotic consumption
increased the size and diversity of protective fecal bifidobacterial populations, which are
often reduced in older people. This study had a slightly longer washout period than the
previous, and had positive results.
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A study using yogurt by Palaria, et al. had a similar design. It was divided into
five consecutive periods: a pre-feeding period (1 week), a feeding period (3 weeks), a
washout period (4 weeks), a second feeding period (3 weeks), and a final washout period
(4 weeks) (45). Fecal samples were collected at the start and at the end of the first week.
During the first feeding period, the subjects daily consumed either 94 g of placebo, which
consisted of milk acidified to pH 4.2 with lactic acid, or 94 g of a drinkable yogurt
containing 109 to 1010 CFU of strain B. animalis subsp. lactis Bb-12 and 1 g of inulin per
serving. The yogurt was prepared with skim milk and a standard yogurt starter blend
consisting of Streptococcus thermophilus and Lactobacillus bulgaricus, together with
the B. animalis subsp. lactis Bb-12 culture and had a final pH of 4.2. Fecal samples were
collected at the end of each of the three (3) weeks. The subjects consumed neither the
yogurt nor the placebo during the subsequent washout period. Single fecal samples were
collected at the end of every two (2) weeks. A live/dead PCR procedure indicated that the
Bb-12 microorganism was detected in the fecal samples was alive. A significant increase
(P < 0.001) in the total bifidobacterial numbers was observed in both groups of subjects
during the final washout period compared to the prefeeding period. This increase in total
bifidobacteria corresponded with a significant decrease (P < 0.05) in numbers of
clostridia but not enterobacteria.
Prebiotic, Probiotic and Synbiotic Ice Cream
Many studies have been conducted to determine if ice cream would be an
effective carrier for prebiotics, probiotics, or synbiotics. These studies were conducted
mostly to determine the palatability or sensory acceptability of these products as well as
their ability to keep the bacteria viable (41, 46).
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The Wood and Lum and Albrecht project objective was to determine consumer
acceptability of ice cream with prebiotic ingredients. A commercial ice cream mix was
made substituting 0%, 10%, 20%, or 30% of the sugar for either Fructooligosaccharides
(FOS) or inulin. Participants rated the synbiotic ice cream for its sensory attributes of
sweetness, smoothness, and vanilla flavor (47, 48). When 10% and 20% inulin ice cream
were compared to the control (0%), no significant differences in sweetness, smoothness,
vanilla flavor or overall acceptability were found (P < 0.05). The 30% inulin ice cream
was significantly less sweet than the control and 10% and 20% inulin ice cream. The 30%
inulin was less smooth and had less vanilla flavor than the control, and was less
acceptable than both the control and the 10% inulin ice cream (P < 0.05). For 10% and
20% FOS ice cream, no significant differences were found in sweetness, smoothness,
vanilla flavor or overall acceptability compared to the control (P < 0.05). These results
suggest that FOS and inulin may be acceptable ingredients in ice cream when substituted
up to 20% of the sugar.
A few studies examined the use of just probiotics in ice cream to determine if it
would be a viable probiotic carrier. The strains used in the first study
included: Lactobacillus acidophilus, Bifidobacterium bifidum. Sensory results were
positive but the bacteria counts decreased throughout the 90-day storage, however did
maintain their probiotic qualities (49). The second study illustrated that ice cream is not
good at maintaining the viability of the bacteria. However, if the ice cream is made with a
prebiotic such as FOS or inulin, these ingredients help to maintain the viability of the
bacteria (50). In both studies, the ice cream was made by inoculating some of the milk
and then adding it after cooling down the rest of the ingredients. Cruz and colleagues
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reviewed the potential for ice cream to be a probiotic food carrier. Two studies with
probiotics in ice cream reported that the bacteria survived the freezing process (51). Only
one study could be found where they actually tested a probiotic ice cream formula in a
human trial to determine its effects. This study examined the impact of probiotic ice
cream consumption on levels of Salivary Mutans Streptococci (SMS) during and after the
trial. They found that the levels of the SMS decreased during treatment, but by six
months post treatment, the SMS levels were similar to baseline (52).
Several studies could be found which examined the effectiveness of prebiotics
and probiotics used together synbiotically. One study examined the differences between
prebiotic, probiotic and synbiotic ice cream. Their probiotic ice cream contained two
Lactobacillus species (L. rhamnosus and L. casei). These were used independently within
fruit or vanilla flavored ice cream. Inulin (2.5%, 5% or 10%) replaced part of the
stabilizer for the prebiotic ice cream and the synbiotic ice cream used either 3 or 6%
inulin with either of the probiotic organisms. All ice cream samples were effective at
maintaining probiotic function (46).
Two UCARE students (Lim and Mills) examined the sensory characteristics of a
synbiotic ice cream in which 10 %, 20% or 30% of the sugar was substituted with either
inulin or fructooligosaccharide (FOS) (53). The probiotic species, Lactobacillus casei
KE99 (0.3g) and Bifidobacterium bifidum (0.3g), were formulated in the ice cream
products to make a synbiotic ice cream. Both probiotics used were purchased as freeze
dried cultures from ProbioFerm in Des Moines, Iowa (54). These probiotics were labeled
as 100% pure and food grade. Their results reported that the 30% FOS negatively
affected the flavor and texture. The addition of inulin did not affect the sweetness,
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smoothness, flavor, texture, and overall acceptability of the ice cream treatments. The
addition of the probiotics did not affect any of the sensory characteristics of the ice cream
samples. Another UCARE student (Irby) then examined the viability of the probiotics
during ice cream storage (55). The results of this study demonstrated that the probiotics,
Lactobacillus casei KE99 (0.3 grams) and Bifidobacterium bifidum (0.3 grams) continued
to be viable over a four month period (120 days), making these bacteria a good choice to
use as a probiotic and the ice cream a good synbiotic carrier. These two strains were the
same strains chosen for our research study.
Recent studies examined the effectiveness of using microencapsulation (MEP) to
determine the effect on bacteria survival within synbiotic ice cream. The results of all the
studies have reported slower reduction in probiotic bacteria over storage time (56-59).
The best results were reported when the MEP bacteria was incorporated into chocolate
particles (57). Overall, all showed MEP to be an effective method for maintaining
probiotic viability within ice cream. These studies were all published after our study
design was set and underway.
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CHAPTER 2
Problem Statement
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Based on the literature review and previous research conducted, the objectives of
our study are to determine if there are any significant gastrointestinal side effects from
consuming synbiotic ice cream as well as to examine how the bacteria counts change
prior to eating the ice cream, during consumption, and post consumption.
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ABSTRACT
Background: Diet is an important factor in gastrointestinal health. A synbiotic food
option utilizing prebiotic and probiotic ingredients may be beneficial for improving
gastrointestinal health.
Objective: To conduct a human subject study of synbiotic ice cream containing prebiotic
(inulin) and two strains of probiotics (Lactobacillus casei KE99 and Bifidobacterium
bifidum) to determine its effectiveness as a carrier for a these ingredients and to identify
any negative gastrointestinal side effects.
Methods: The study started with baseline data collection including a food frequency, a
three day food recall, and one stool sample. The study was a 12 week crossover design
with three weeks consuming placebo or treatment ice cream then a three week washout
period. After, participants would switch to the other ice cream. Fecal samples were
collected to examine bacteria level changes. Participants kept a log book during the two
treatment periods to track gastrointestinal symptoms and record amount of ice cream
consumed.
Results: There was a not a significant difference in amount of ice cream consumed
during placebo and treatment periods; t(11)= 0.31, p = 0.98. Change in reported
flatulence level was not statistically significant; t(11)= -0.82, p = 0.43. There was no
significant change in number of stools per day between treatment and control; t(11)= 2.09, p = 0.06. Change in Bristol scale values during placebo and treatment was not
statistically significant; t(11)= -0.71, p = 0.49.There was not significant difference in the
Bifidobacterium bifido values during treatment (M=47.13, SD=103.22) and control
(M=24.11, SD=80.29); t(12)= 1.72, p = 0.11.
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Conclusion: Synbiotic ice cream could be an effective carrier for probiotics and
prebiotics. Consumption did not cause an increase in gastrointestinal symptoms. The
results of the bacteria level change were not significant. Further research is needed.

Key words: probiotic, synbiotic, prebiotic, synbiotic ice cream, Bifidobacterium bifidum,
Lactobacillus casei KE99
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INTRODUCTION
Human gastrointestinal health may be improved by the consumption of prebiotic
food ingredients and foods containing probiotic microorganisms such Lactobacillus and
Bifidobacterium (1).
Prebiotics are defined as “nondigestable food ingredients that have a beneficial
impact on the host by selectively stimulating the growth and/or activity of one or a
limited number of bacteria in the colon and thus improving host health” (2, 3). These
prebiotics are nondigestable because the host, humans, lack the enzymes required to
break the beta (β) bonds that hold the prebiotic together. These prebiotics reach the colon
still intact since the host cannot break them down. Certain strains of beneficial bacteria
found in the gastrointestinal tract, especially Bifidobacterium and Lactobacillus, are able
to break the β bonds in the prebiotics providing an energy source for the bacteria and as
well creating byproducts of fermentation that are beneficial to the host.
Nondigestable fructooligofructoses, including inulin, are prebiotic ingredients that
have been shown to have positive effects on host health, reducing the risk of
gastrointestinal diseases such as diverticulosis, diverticulitis, and colon cancer (4-9).
Inulin is a generic term that covers all β (1←2) linear molecules and their degree of
polymerization (DP) varies from 2 to ~60 units (10, 11). The inulin then serves as a
growth substrate for the gut microflora (8, 12, 13).
Mixed findings have been reported for the consumption of inulin or oligofructoses
(8, 14-16). Results depend on the amount and type of fructooligofructose, consumed,
length of time consumed, and wash out periods between treatments. Some subjects have
experienced side effects from consuming inulin that range from an increased level of
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flatulence to possible constipation and/or diarrhea (4). Findings show that bacteria
ferment different chain lengths at different speeds. The differing speeds may be
correlated to location of fermentation, with the longer chains being broken down in the
more distal regions at a slower rate. The longer chains at a slower rate could lead to less
side effects, including less flatulence (17). A beneficial dose of 20g per day has been
shown to be effective in producing an increase in bifidobacteria, although considerable
individual variation existed (8). When Bifidobacteria is more predominant in the gut,
such as the case when inulin and other frutooligofructoses are ingested in the proper
amounts, the number of pathogenic bacteria such as E. coli and Clostridia are decreased
by competitive inhibition which can improve GI health (7, 12, 13).
Numerous human studies have been conducted that demonstrate the consumption
of bifidobactera increases colonic bifidiobacteria, and when stopped, levels return to
baseline (10, 18, 19). In vitro studies demonstrated that fermentation and growth rates of
bifidobacteria increase when short chain oligofructose is the carbon source and that the
chain length affects the microflora composition and activity (11, 14, 20, 21). According
to a Health and Human Services report, previous research with probiotics has been very
inconsistent when describing the intervention, reporting the results of the intervention,
and providing information regarding genus, species, and strain. Improving these aspects
in future research was recommended (22). The safety and functionality of these products
is dependent on labeling accuracy. Unfortunately accurate labelling has not always been
found (23-25). Rijkers and colleagues noted that adverse events were not well described
and the food matrix used for the probiotic was not identified (26).
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Recently, many studies have investigated the co-administration of prebiotics and
probiotics called synbiotics. Synbiotics may help enhance the benefits provided by either
pre- or probiotic supplementation (3, 27, 28). Studies have been conducted to evaluate the
sensory properties of either probiotic, prebiotic, and synbiotic ice creams (29-31). For
their probiotic ice cream, two Lactobacillus species (L. rhamnosus and L. casei) were
used independently with either fruit or vanilla flavors. Inulin (2.5%, 5% or 10%) replaced
part of the stabilizer for the prebiotic ice cream and the synbiotic ice cream used either 3
or 6% inulin with either of the probiotic organisms (29). Another study tested the
palatability of prebiotics replacing 10%, 20%, and 30% of the sweetener with inulin or
FOS. The 10% was found to be the most tolerated with the 20% being acceptable and the
30% not accepted. This same prebiotic ice cream was then tested as a synbiotic mixture
with probiotic species, Lactobacillus casei KE99 (0.3g) and Bifidobacterium bifidum
(0.3g) added and the same tolerance levels were found (31). Cruz and colleagues
reviewed the potential for ice cream to be a probiotic food carrier. Two studies with
probiotics in ice cream showed they survived the freezing process (30). Clinical studies
have not been conducted with the probiotic, prebiotic or synbiotic ice cream
formulations.
The objective to our study was to determine if there are any significant
gastrointestinal side effects from consuming synbiotic ice cream as well as to examine
how the bacteria counts change prior to eating the ice cream, during consumption, and
post consumption. For this study a randomized, blind, crossover, placebo controlled
human trial of synbiotic ice cream containing the prebiotic inulin and probiotics
Lactobacillus casei KE99 and Bifidobacterium bifidum was performed to test the
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effectiveness of ice cream as a carrier for prebiotic and probiotic ingredients and
examined the impact on gastrointestinal health.
SUBJECTS AND METHODS
Study Design
The study was a 13 week blind, placebo-controlled crossover trial where
participants were randomly assigned and either consumed synbiotic ice cream or plain
(placebo) ice cream for a three-week treatment period followed by three-week washout
period as suggested by the design of other studies and the findings on these particular
bacteria strains (32-34). The three-weeks of treatment followed by three-weeks of
washout was then repeated with the opposite ice cream type, either synbiotic or placebo.
Baseline data was collected the week prior to the start of the first treatment of the
study. At the start of each week of the three week treatment periods, participants received
seven one-half cup containers of ice cream, to be consumed daily for the next week. At
the end of that week, participants brought in their stool sample and received next week’s
supply of ice cream. In blinded fashion, these portion cups for the treatment and placebo
were identically packaged
Ice Cream Formulation
The ice cream formulation used was the same formulation that had been tested
previously for sensory qualities and probiotic stability. The bacteria were pure freezedried food grade probiotics (Lactobacillus casei KE99 and Bifidobacterium bifidum)
purchased from ProbioFerm in Des Moines, IA. In each serving of synbiotic ice cream
participants were consuming approximately 0.7 g of inulin and 0.017 grams or 1 billion
(1 x 109) CFU per serving of the probiotic bacteria. All ice cream for the synbiotic
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treatment as well as the control was made prior to starting a treatment period. The
synbiotic ice cream was made using the following formulation (Appendix 1):

Ingredients
Milk
Cream
Nonfat Dry
Milk
Corn
Syrup
Solids
Stabilizer
Sugar
Inulin
B.bifidum
Lacto casei

Synbiotic
Control W/10% inulin
amounts in grams
595
595
202
202
50

50

45
7
100
0
0
0

45
7
90
10
0.3
0.3

To prepare the ice cream: Dry ingredients were mixed in with the wet ingredients
and the ice cream preparation was heated in a microwave during two separate intervals.
Inulin is obtained in powder form from the manufacturer SourceNaturals. After four
minutes, the ice cream preparation was stirred and then put back in the microwave for
three and a half minutes to solubilize the stabilizer. After heating, the ice cream batch are
cooled using an ice bath until they reached a temperature below 40°C so that the
probiotics could be at a temperature in which their viability would not compromised.
Bifidobacterium bifidum and Lactobacillus casei KE99 were obtained from ProBioFerm
(Des Moines, IA) in 50 billion colon forming units (CFU) per gram. After adding the
probiotics the batch can be poured into an ice cream maker and removed once the ice
cream is done churning. Note: These steps are followed for both recipes minus the
addition of the probiotics and prebiotics to the control. Once the machine finished the ice
cream was measured out into half cup servings and stored in individual plastic containers
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with lids. These were then stored in a standard freezer until they were given to the
participants.
Participants
The study was approved by the Institutional Review Board and all volunteers
gave written informed consent prior to the start of the project. Participants were recruited
through posters placed in campus buildings (Appendix 2). Emails were sent out to the
current and previous class of dietetic interns upon approval of the internship program
director (Appendix 3). Subjects had to be a student or faculty member of University of
Nebraska – Lincoln for ease of safety with regard to any potential health concerns. The
participants filled out a screening tool to determine if they met the requirements to be
participants (Appendix 4). Potential subjects with a history of colon diseases,
diverticulosis or diverticulitis, chronic diarrhea or constipation, and recent antibiotics in
the last six weeks were excluded from the study, as were women who were pregnant or
breastfeeding. Participants were asked to read through and sign a document of informed
consent (Appendix 5). All participants were asked to continue following their normal diet
routine and not modify it in any way, In particular, they were asked not to increase
probiotic or prebiotic consumption from their usual intake.
Sampling
A food frequency, a three-day diet recall, and a stool sample were collected at
baseline (Appendix 6). Then participants filled out a daily log book during both
treatments periods to track stool/flatulence frequency, stool consistency, and percent of
ice cream consumed as well as providing them with space to log any additional
comments (Appendix 7). The participants were asked to provide a total of 19 stool
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samples throughout the study; one at the end of each week, plus one for each of the first
three days of the washout periods. These were to be collected on days 0, 7, 14, 21, 22, 23,
24, 28, 35, 42, 49, 56, 63, 64, 65, 66, 70, 77, 84 (Appendix 8). Samples were brought to
the researcher utilizing the collection tubs that the participants used to collect the
samples. These samples were held at -20°C until processing.
Food recall and Food Frequency
Food recalls were collected and analyzed for each participant to determine a
baseline of how much fiber they usually consume as well as how many probiotic food
items they usually consume. The food recalls were analyzed using USDA’s SuperTracker
to get a consistent and accurate picture of the participants’ usual intake (35) (example
pages Appendix 9-10). The food frequency was used as a supplemental piece to view
how much the participants reported that they usually consume of various prebiotic and
probiotic food sources. The food frequency tool was designed specifically for this study
but utilized information on high and moderate prebiotic and probiotic food sources.
Log book
Participants were given log books to keep track of the following during the two
treatment periods: ice cream consumed (percentage scale from 0% to 100%), flatulence
level (Likert scale from 0 to 10), number of stools, and the Bristol scale for stool
consistency.
Preparation of cultures
In preparation for analysis of the fecal samples procedures had to be completed on
the same pure freeze dried cultures from ProbioFerm (Des Moines, IA) used within the
ice cream. The cultures were grown in Difco Lactobacilli MRS Agar and Difco

40
Lactobacilli MRS broth (Becton, Dickinson and Co., Franklin Lakes, NJ) and incubated
in an airtight container with an GasPak™ EZ Anaeobe Container System with Indicator
(Becton, Dickinson and Co., Sparks, MD) at 37°C overnight. Growth was checked the
following day. If there was not enough growth they were left in overnight to continue
growing. If growth was seen the sample was removed from the incubator and the next
steps were taken. Growth on the plate was examined. One or two well isolated colonies
would be picked with a sterile loop and streaked onto a new MRS agar plate. The
incubation step was repeated as above followed by streaking of one or two well isolated
colonies from each plate. This was done a minimum of four times to ensure purity of the
culture.
An isolated colony was picked from each plate and stained using a gram stain kit.
Both B.bifidum and L.casei are gram positive rods found in clusters, pairs, or
independently. The gram stained cultures were examined under a microscope to
determine if the cultures were the correct stain color, correct shape, and colony formation
style. One or two times the slides showed a mix of cocci and rods. The steps of isolation,
growth, and staining were repeated until specimens under the microscope looked correct.
Once the gram stain results showed the correct shape, colony formation, and gram stain
results, isolated colonies were picked with a sterilized loop and placed in Difco
Lactobacilli MRS broth (Becton, Dickinson and Co., Franklin Lakes, NJ) for a final
incubation with the same condition as previously described. The next day samples were
taken out and vortexed briefly to mix. 1 mL of sample was extracted and centrifuged at
1,700xg for three minutes, supernatant was discarded.

41
DNA was extracted using QuickExtract™ Bacterial DNA Extraction Kit
(Epicentre, Madison, WI) with the following changes to the protocol: The sample pellet
from above was used and 500 mL quick extract was added to the tube containing the
pellet. Sample was Vortexed for 45 seconds, incubated at 65°C for ten minutes, vortexed
for 30 seconds, then incubated at 95°C for two minutes.
The bacterial DNA was then amplified using primers 27F and 1492R (barcoded)
(36). The PCR reactions were performed in 20 µL volumes and contained 0.5 L of Terra
DNA polymerase (Clontech Laboratories, Mountain view, CA), 10 L reaction buffer,
250 nL of each primer, and 1l of the extracted nucleic acid template or no-template
control. The cycling conditions were an initial denaturation of 98C for 2 minutes,
followed by 35 cycles of 98C for 30 seconds, 52C for 30 seconds, and 68C for 90
seconds; and a final extension of 68C for 4 minutes. Following amplification, PCR
products were analyzed on a 1.5% agarose gel to confirm correct product size.
Once completed the concentration level of each sample was checked. This was
done using the NanoDrop® ND-1000 Spectrophotometer. Cultures were then diluted with
PCR grade water to get all samples to desired level of 10-15 ng/µL. 10 µL of sample was
combined with 2 µL of 518R primer and sent to Eurofins genomics (Eurofins MWG
Operon LLC., Louisville, KY) for sequencing. Despite the fact that the cultures were
isolated from samples grown from the pure freeze dried cultures the sequencing results
either had too many unidentified bases (N) in sequencing to have a clear result or they
matched better to a different bacteria. Both of these results meant that the sequence was
not strong enough, either due to lack of base pair information or impurity, to be used to
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make probes. As a result it was determined that primers for the two bacteria should be
used.
Primer Selection
Several sets of primers were designed using the primer designed software at IDT
(http://www.idtdna.com/primerquest/home/index) using default parameters, for the
bacterial strains to determine the one that worked best with our specific cultures. To
select the best set of primers, the primer pairs were tested against four pure cultures of
each B.bifidum and L.casei by using PCR and gel electrophoresis to determine which
would amplify the desired cultures and not the others (36). The PCR reactions were
performed in 20 µL volumes and contained 0.5 L of Terra DNA polymerase (Clontech
Laboratories, Mountain view, CA), 10 L reaction buffer, 250 nL of each primer, and 1l
of the extracted nucleic acid template or no-template control. The cycling conditions
were an initial denaturation of 98C for 2 minutes, followed by 35 cycles of 98C for 10
seconds, 52C for 30 seconds, and 68C for 60 seconds; and a final extension of 68C for
4 minutes. Following amplification, PCR products were analyzed on a 1.5% agarose gel
to determine what the primers had amplified. Initially, three sets of primers for both
B.bifidum and L.casei were purchased. The first attempt with all primers and all eight
samples resulted in one promising primer set for each which showed amplification of the
matching four samples and no amplification of the other four. These two were run
through PCR again with the same volume and mixture. The cycling conditions were
modified so that the middle part of the cycle (previously 52C for 30 seconds) had a
gradient temperature of 54°C, 56°C, 58°C, 60°C, 62°C. The results were examined on a
1.5% agarose gel. The results were that the B.bifidum 2 primer set was selected and
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determined to work best at 60°C annealing temperature (see Appendix 11 for full
sequence information and Figure 1 for gel image). Unfortunately, the gel results showed
that the L.casei primer had amplified all eight samples and not just the four L.casei
samples illustrating that it was not selective enough to be used (see Figure 1).
The selected B.bifidum primer and all three L.casei primers were tested again
using SYBR® Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA) this
time since this would be the mix used with the participant samples for quantification of
the bacteria. The PCR reactions were performed in 15 µL volumes and contained 7.5 L
SYBR® Green PCR Master Mix, 250 nL of each primer and 4l of the extracted nucleic
acid template. The cycling conditions were an initial denaturation of 95C for 2 minutes,
followed by 35 cycles of 95C for 10 seconds, gradient of 54C and 60C for 30 seconds,
and 68 C for 60 seconds; and a final extension of 68 C for 5 minutes. This gave the
same results as the before with B.bifidum primer 2 being selected L.casei primers not
selective enough. Six new sets of L.casei primers were purchased for testing. These were
tested with all four L.casei pure cultures and one B.bifidum culture and the same SYBR®
Green PCR in volume and ratios listed above. The cycling conditions were modified to
include a wider temperature gradient with a gradient temperature set of 54°C, 56°C,
58°C, 60°C, 62°C. The results from testing with these new L.casei primers still resulted
in no L.casei primer being selected due to either lack of selectivity and incorrect
selectivity, meaning it did not amplify this exact strain (see Figure 2). Due to time
constraints with this project the next steps were completed using just the primers selected
for B.bifidum.
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Fecal samples analysis
With the participant samples, the PowerMag™ Soil DNA Isolation Kit (Mo Bio
Laboratories, Inc., Carlsbad, CA) was used to extract the DNA from the stool samples
following the manufacturer’s protocol with the following modifications: the 2 beadbeating steps were performed in a TissueLyser (QIAGEN Inc., Valencia, CA) and
samples were incubated in a 95 °C water bath for 5 min between bead-beading steps.
After DNA was extracted from the samples, their concentration levels were tested
using the NanoDrop® ND-1000 Spectrophotometer. Once the concentration was
identified the epMotion M5073 liquid handler (Eppendorf AG, Hamburg, Germany) was
used to normalize all samples to 10ng/L. This way all concentration levels were
equivalent before quantifying the bacteria enabling us to get a more accurate picture of
the level changes throughout treatment.
The samples were then processed through quantification Polymerase Chain
Reaction (qPCR) using the 7900HT Fast Real-Time PCR System in duplicate. All these
were done using the same SYBR® Green PCR Master Mix volumes and ratios mentioned
above. The V3 region of the 16S rRNA gene specific to eubacterial communities was
amplified using universal primers 341F and 518R (barcoded). The cycling conditions
were an initial denaturation of 98C for 10 minutes, followed by 30 cycles of 95C for 30
seconds, 52C for 30 seconds, and 72C for 30 seconds; and a dissociation step of 95C
for 15 seconds, 60C for 15 seconds, and 95C for 15 seconds. Next the samples were
processed through qPCR with the selected B.bifidum primers. The cycling conditions
were an initial denaturation of 98C for 2 minutes, followed by 45 cycles of 95C for 10
seconds, 60C for 30 seconds, and 68C for 45 seconds; and a dissociation step of 95C
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for 15 seconds, 60C for 15 seconds, and 95C for 15 seconds. The dissociation curve for
each of the reactions was examined upon completion and samples with a substandard
curve were re-done (example of one of the Dissociation curves found Appendix 12). The
quantified results of the sample sets for the 16s and the Bifidobacteria were averaged for
each participant. These were then quantified using Δct, ΔΔct and fold change (2^(-ΔΔct)).
The data from these experiments was analyzed using SPSS using a two tailed t-test to
compare the changes in Bifidobacteria count between the treatment and control times of
the study.
Objective
The objective of this study was to conduct a clinical feeding study to determine if
synbiotic ice cream is a viable food carrier for prebiotic (inulin) and probiotic
(Lactobacillus casei KE99 and Bifidobacterium bifidum) food ingredients and to
determine if it had any negative gastrointestinal effects on the participants.
RESULTS and DISCUSSION
Results
Demographic
Initially, 15 participants started the study. The study ended with 13 participants;
two males and 11 females or 13% males and 87% females (Figure 3) Participants were
between 21 and 28 years (Figure 4) The average age was 23 years.
Food Recall and Food Frequency
Prior to the start of the study, participants filled out a food frequency and a food
recall. The food frequency showed participants consumed an average of 3 probiotic foods
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per week and 36 prebiotic food per week (Figure 5). The food recall results showed an
average of 19.5 grams of fiber per day and 0.3 probiotics a day (Figures 6 & 7).
Log Book
Results of the participants log book (Appendix 7) are reported in the table 5.
There was a not a significant difference in the scores for the percentage (from 0%-100%)
of amount of ice cream consumed during the placebo period (M=92.76, SD=9.74) and the
amount of ice cream consumed during the treatment period (M=92.67, SD=9.27); t(11)=
0.31, p = 0.98. There was not a significant difference in the reported flatulence level
(likert scale from 0-10) during placebo (M=3.74, SD=1.56) and during treatment
(M=4.02, SD=1.61) periods; t(11)= -0.82, p = 0.43. There was a not a significant
difference in the reported number of stools per day during placebo (M=1.43, SD=0.51)
and during treatment (M=1.69, SD=0.74) periods; t(11)= -2.09, p = 0.06. There was not a
significant difference in the reported number of stools per day during placebo (M=1.43,
SD=0.51) and during treatment (M=1.69, SD=0.74) periods; t(11)= -2.09, p = 0.06. There
was not significant difference in the reported Bristol scale values per day during placebo
(M=3.18, SD=0.17) and during treatment (M=3.35, SD=0.82) periods; t(11)= -0.71, p =
0.49.
Bacterial
There was not a significant difference in the Bifidobacterium bifido fold change
values over the treatment (M=47.13, SD=103.22) and over the control (M=24.11,
SD=80.29) periods; t(12)= 1.72, p = 0.11 (Table 3.6).
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Discussion
After collecting and analyzing all of the samples and materials the treatments
shows no statistically significant impact on gastrointestinal symptoms of the participants.
The lab analysis results show no statistically significant change as to effectiveness and
impact on colonization and viability in the gastrointestinal tract. This lack of statistical
significance was mostly due to the small sample size.
Participation
Two participants did not complete the study. One dropped out in two weeks after
being placed on antibiotic treatment, thus disqualifying them from continuing with the
study. Another participant dropped prior to the midpoint of the study due to time
constraints. No participants discontinued participation due to any complications caused
by treatment from the study. The remaining thirteen participants completed the study. All
participants missed at least one sample collection during the study either due to travelling
or because they were simply unable to provide a sample that day. In total, as seen in fig. 1
two males and 11 females completed the study that originally comprised thirteen female
and two male participants.
Food recall and food frequency
The results of the food recall showed that the participants had a wide range of
normal fiber intake, with seven grams being the lowest and 30 grams being the highest.
The average fiber intake was 19.5 grams, and the average consumption for probiotics was
0.3 foods per day. The food frequency result showed that most participants consumed
prebiotic foods with lowest consumption being one prebiotic food a day and highest
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being approximately seven per day. Consumption of probiotics was lower. The highest
was nine probiotic foods per week and the lowest was zero (table 4).
Log Book
The two-tailed t-test results showed no significance for any of the reported data
(table 5 & 8). This was the desired result. The amount of ice cream consumed during the
treatment and control was not statistically different and looking at the means show they
are very close similar during both periods. The paired samples correlations showed that
the change in flatulence level from control to treatment had a strong correlation (0.71)
which was statistically significant (0.009). This means that even though the actual level
of change was not statistically significant, partially due to sample size, there is a
significant level of correlation between when participants were on the treatment and their
increase in flatulence level. The same result was shown for number of stools. The paired
samples correlation showed number of stools and treatment had a close correlation (0.82)
which was significant (0.001). This means that even though the level of overall change
was not significant the correlation between the change and the treatment was significant.
Bacteria results; QPCR
The overall statistical analysis for the means during the treatment and control
periods showed no statistical significance (p = 0.11) but did have a clear difference in
means (treatment = 47.13; control = 24.11) (table 3.6). The results of plotting each
individual’s fold change values over the study were not as expected. The expectation was
to see an increase in B.bifidum count during treatment and a decrease in B.bifidum during
washout following the treatment while seeing levels mostly near baseline throughout the
rest of the study. The results instead showed spikes during control periods that should not
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have been there (table 3.7 parts 1 & 2). Further testing needs to be done to determine
exact cause of the inconsistencies. Many difficulties arose with respect to getting the lab
procedures to run according to the study plan. Originally, the study design called for
making probes specific to the bacteria strains being used.
Conclusion
The synbiotic ice cream did not have any negative impacts on the participants
with regard to gastrointestinal symptoms. The results of the bacteria level change were
statistically insignificant and further research is needed.
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Figure 1 B.bifidum and L.casei gel results
The results for the gel electrophoresis that allowed us to select the correct temperature for
the bifidobacterium bifido primer. The first five sample were the primers with b.bifidum
with a temperature gradient of 54°C, 56°C, 58°C, 60°C, 62°C. The next five samples
were the primers with Lactobacillus casei with the same temperature. This showed that
the primers did not amplify the other bacteria strain and resulted in choosing 60°C as the
annealing temperature. The last 10 samples were the B.bifidum and L.cause samples with
the L.casei primer in the same order as the first 10. This illustrated that the primer was
not selective enough.

Figure 2 L.casei primer test results
The gel electrophoresis for one of the gradient temperature Lactobacillus casei primers
test. The red boxed area shows the temperature graident of 54°C, 56°C, 58°C, 60°C,
62°C of both L.casei primers with bifidobacterium bifido. The first five are with primer 4
and second five are with primer 5. The brightly illuminated samples following were 4
different L.casei cultures on the same temperature gradient with primer 4 (blue box). The
remaining samples were the same 4 L.casei cultures on the same gradient with primer 5
(green boxes). These results show that the primers either amplified everything or almost
nothing.
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Figure 3: Gender of participants
Participants who completed the study (11 females and 2 males), separated by gender with
the numbers representing percentage of males and females.

Gender of Participants

male
15%

female
85%

male

female

Figure 4: Age of participants
Participant’s ages. Showing number of participants of each age with age in years on the
y-axis and number of participants that age across.
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Figure 5: Food Frequency results
Food frequency results for probiotic and prebiotic foods. Showing participants and on far
right the average on the x-axis. The number of times they were consumed per week is
represented on the y-axis
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Figure 6: Diet Recall Fiber intake
The average results from each participant’s 3-day food recall for daily fiber intake. Each
value given number 1-13 represents an individual participant’s intake in grams. The final
value on the far right of the x-axis is the overall participant average
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Figure 7: Diet Recall Probiotic Intake
The average results from each participant’s 3-day food recall for daily fiber intake. Each
value given number 1-13 represents an individual participant’s intake in grams. The final
value on the far right of the x-axis is the overall participant average
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Table 1: Log book t-test results
A two tailed t-test was conducted with a 95% confidence interval and 11 degrees of freedom. The table shows the averages for
amount of ice cream consumed, flatulence level, number of stools, and what the Bristol rating for stool consistency was during
the control and treatment periods of the study as reported in mean and standard deviation. The mean difference between values
during the control and treatment are reported followed by their confidence interval and t-score. All the p values were not
significant (p > 0.05).

Amount consumed
(0%-100%)
Flatulence
(0-10 Likert scale)
0 = none, 10 = constant
Number of Stool (0-10)
Bristol Rating (0-7)
0 = hard lumps, 7 = liquid

control
(placebo ice
cream)

treatment
(synbiotic ice
cream)

Mean
Difference

95% CI

92.76 ± 9.74

92.67 ± 9.27

.08929

6.29 to 6.47

.031

0.98

3.74 ± 1.56

4.02 ± 1.61

-.28423

1.05 to 0.48

-.817

0.43

1.4 ± 0.51

1.69 ± 0.74

-.26084

0.54 to 0.01

-2.087

0.06

3.18 ± 0.58

3.35 ± 0.82

-.17484

0.72 to 0.37

-.707

0.49

t score p value

Table 2: B.bifidum qPCR t-test results This was a two tailed t-test conducted with a 95% confidence interval and a degrees
of freedom of 12. It shows the fold change averages for Bifidobacterium bifidum during the control period of the study and
during the synbiotic treatment period. The mean difference is the difference between the two means. The p value was not
statistically significant (p > 0.05)

B. bifidum
fold change

control
(placebo ice
cream)

treatment
(synbiotic ice
cream)

Mean
Difference

95% CI

t score

p value

47.13 ± 103.22

24.11 ± 80.29

23.02367

6.12 to 52.16

1.72

0.111
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Table 3: B.bifidum qPCR values
The quantified values show the fold change for B.bifidum as calculated with the qPCR
data for each collection during treatment and washout periods are given. Participants are
listed vertically, and data for each participant is listed horizontally across the table.
person
1
2
3
4
6
7
8
9
10
12
13
14
15

treatment
washout
day 7 day 14 day 21 day 1 day 2 day 3 day 7 day 14 day 21
0.81
1.15
0.17 0.05
0.35 0.48
0.41
0.00
239.11
2.40
1.33 2.71 0.36 5.00 7.42
9.41
3.54
0.14
0.08
0.10 0.02 0.08 0.03
5.56
1.14
0.26
5.36 0.00 1.15
0.00
0.00
474.05
4.01
1.56
0.93 4.15 0.14
0.00
0.76
1.24
0.43
0.22 1.39 0.00 0.01 0.15
0.18
2.74
0.84
0.81
3.17 0.14 0.73 0.79 0.30
0.16
0.00
0.61
3.14
0.53 1.99 0.72 0.44
2.28
1.33
6.07
9.11
1.12 1.24 0.07
19.24
0.48
0.61
1.45 4.59 0.00
0.13
0.00 492.46
0.41
6.96
0.43
1.25
5.95
7.14
4.95
0.02
0.07 0.72
3.41
0.11
102.66 451.54 504.44 74.74 61.96 74.74 23.33 919.91 77.78

60
Table 4: B.bifidum qPCR values
The quantified values show the fold change for B.bifidum as calculated with the qPCR
data for each collection during the control and washout periods are given. Participants are
listed vertically, and data for each participant is listed horizontally across the table.
control
washout
person day 7 day 14 day 21 day 1
day 2 day 3 day 7 day 14 day 21
1
0.43
0.32
0.00
0.12 0.01
1.52
1.02
1.21
2
1.39
2.09
0.70
1.69 9.48
0.00
3.70
0.47
3
0.38
2.26
1.62
1.26
0.34
5.87
0.67
4
0.42
1.10
2.37
0.00
0.01 0.03
3.55
4.50
6
1.44
3.90
0.00
0.67
0.10
0.19
7
0.45
0.51
1.54
0.70
1.42
8
6.89
0.01
3.31
1.97
0.00 0.00 16.77
2.10
0.37
9
0.65
3.45
0.14
1.88
4.54 0.02
1.14
0.66
0.41
10
9.36
0.70
28.76
6.70
12
2.68
0.08
0.12
0.46
0.06
13
1.79
1.30
1.50
0.78 65.29
14
1.43
0.11
0.37
3.17
0.17
15 830.89
0.00 43.00 139.99
9.58 47.62 110.36 726.05 186.92

Table 5: Log Book correlations
The table shows the correlation between the change in means during the control and
treatment periods as well as its significance level for the information reported in the log
books.
Correlation

p value

Amount consumed (0%-100%)

0.443

0.15

Flatulence(0-10 Likert scale)
0 = none, 10 = constant

0.712

0.009

Number of Stool (0-10)

.822

.001

Bristol Rating (0-7)
0 = hard lumps, 7 = liquid

.284

.372
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Chapter 4
Implications
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Limitations
Participants were allowed to follow their normal diet instead of being put on the
same diet to limit confounding factors. As all participants followed their own diet pattern,
this could result in statistical inconsistencies. The smaller amounts of prebiotics and
probiotics added to the ice cream may have been too small to achieve the desired result.
Sample size itself was also a limitation as there were just 13 participants. A larger sample
size would have been preferable to determine statistical significance. Purity of the freeze
dried bacteria was another limiting factor. Many challenges with the lab analysis were
related to issues with the purity level of the bacteria cultures.
When new fresh cultures were isolated from the freeze dried bacteria, their
sequencing results came back more contaminated than the previous times. The results for
both Bifidobacterium bifido and Lactobacillus casei came back as matching Pediococcus
acidilactici. Pediococcus acidilactici is a gram-positive cocci that is anaerobic and
homofermentative. It is able to grow in a variety of temperatures, pH, and osmotic
pressure and is able to colonize the digestive tract. This probiotic is also available from
the company where the probiotics used in this study were purchased. Based on the results
of the analysis and the difficulty with sequencing the bacteria it seems plausible that the
samples were contaminated before delivery. As only the bacteria strains used were being
quantified, if the samples did not contain 100% the bacteria stated on the packaging, the
probiotic impact could have been lower, limiting our ability to obtain clear results.
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Further Research
Based on the results and new research in publication continued research would be
more efficacious with cultures that can be proven to be 100% pure. Future studies should
try using microencapsulated probiotics to help the bacteria survive through the stomach.
To have a better, the quantity of the probiotics and prebiotics added to the ice cream
could be increased. A larger sample size would be beneficial in understanding the impact
of the synbiotic on the participants. Lastly, instead of examining the changing level of the
strains added, examining, the change in the overall microbiome could provide a clearer
image of the impact this product has on imparting health benefits on the consumer.
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Appendix 1. Ice cream formulation and directions followed.

Ice Cream Recipes and directions
Synbiotic
Ingredients Control W/10% inulin
amounts in grams
Milk
595
595
Cream
202
202
Nonfat Dry
Milk
50
50
Corn Syrup
Solids
45
45
Stabilizer
7
7
Sugar
100
90
Inulin
0
10
B.bifidum
0
0.3
Lacto casei
0
0.3
To prepare the ice cream:
1. Dry ingredients were mixed in with the wet ingredients and the ice cream
preparation was heated in a microwave during two separate intervals. Inulin is
obtained in powder form from the manufacturer SourceNaturals.
2. After 4 minutes, the ice cream preparation was stirred and then put back in the
microwave for 3 ½ minutes to solubilize the stabilizer.
3. After heating, the ice cream batch are cooled using an ice bath until they reached a
temperature below 40° C so that the probiotics could be at a temperature in which
their viability would not compromised. Bifidobacterium bifidum and Lactobacillus
casei KE99 were obtained from ProBioFerm in 50 billion colon forming units (CFU)
per gram.
4. After adding the probiotics the batch can be poured into an ice cream maker and
removed once the ice cream is done churning.

Note: These steps are followed for both recipes minus the addition of the probiotics and
prebiotics to the control.
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Appendix 2. Recruitment poster
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Appendix 3. Recruitment letter
Recruitment Letter
Hello, my name is Erin McNamara. I am a graduate student working towards my Masters
degree in Nutrition and Health Promotion. To further the research of my thesis project, I
would like to solicit your help. I am looking for participants who are willing to participate
in a 13 week study on the effect of synbiotic ice cream on helpful gut bacteria. The study
is for a synbiotic ice cream which contains the prebiotic ingredient inulin (fiber) and
probiotics (helpful bacteria) Lactobacillus casei and Bifidobacterium bifido. There will
be an initial week where we collect baseline data including 1 stool sample and a 3 day
diet diary. Then there will be 2, 3-week treatment periods or feeding periods, where you
will consume either the synbiotic ice cream or plain vanilla ice cream. In each of the
feeding periods you would consume a ½ cup serving of vanilla ice cream, either the plain
vanilla or the synbiotic, once a day and keep a brief journal of different aspects of how
you feel. These treatment periods will each be followed by a 3 week wash out period
where you follow your normal diet. You will be asked to provide 19 stool samples at
different stages in the study so we can track the levels of the two helpful bacteria.
Compensation for your efforts would be given upon completion or termination of
participation in the study as one lump sum in the form of a Walmart gift card. You will
be given $25 for participation and an additional $5 per stool sample to total up to $120.
To help further probiotic and prebiotic nutrition research, I ask for your support and
participation in this study. For more information and to participate please use the below
contact information.

Thank you,
Erin McNamara
University of Nebraska - Lincoln
Department of Nutrition and Health Sciences
Lincoln, NE 68583-0806
Phone: 402-206-1433
Email: erinmm88@gmail.com
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Appendix 4. Screening Questionnaire

Screening questionnaire
1. Are you over 19 years of age?

Yes

No

2. Are you female

Yes

No

If yes, are you currently pregnant or breastfeeding?

Yes

No

If yes, are you post menopausal?

Yes

No

3. Do you have chronic diarrhea or constipation?

Yes

No

4. Do you have diverticulosis or diverticulitis?

Yes

No

5. Do you currently consume probiotics?

Yes

No

Yes

No

Yes

No

Yes

No

If yes how often?
6. Do you currently consume prebiotics?
If yes how often?
7. Are you currently or have recently taken antibiotics?
If so when and for how long?
8. Were you breastfed as an infant?
If yes for how long?

Uncertain
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Appendix 5. Letter of informed consent

____________________________________________________
College of Education and Human Sciences
Department of Nutrition and Health Sciences

Informed Consent Form
Consent Form for Participation in a Research Study
Title of Research Project: The effect of Synbiotic ice cream on gut bacteria viability in
the GI tract
Principal Investigator: Erin McNamara, BS, RD
email: erinmm88@gmail.com
phone: 402-206-1433
Faculty Advisor: Dr. Julie A. Albrecht, PhD, RD
email: jalbrecht@unl.edu
phone: 402-472-8884
Introduction:
You are invited to participate in a research study to determine the effect of synbiotic ice
cream on gut bacteria viability. Synbiotic dietary supplements are made of prebiotics—
fiber--combined with probiotics--helpful bacteria. This consent form will give you the
information you will need to understand why this study is being done and why you are
being invited to participate. It will also describe what you will need to do to participate and
any known risks, inconveniences or discomforts that you may have while participating. You
are encouraged to think this over. You are also encouraged to ask questions now and at
any time. If you decide to participate, you will be asked to sign this form and it will be a
record of your agreement to participate. This process is called ‘informed consent.’ You will
receive a copy of this form for your records
Purpose of the study:
The purpose of this study is to determine if regular consumption of ice cream containing
a synbiotic blend of fiber, inulin, and helpful bacteria--Bifidobacterium bifidum and
Lactobacillus casei--will increase the levels of these two helpful bacteria in the gut.
Procedures:
If you agree to participate in this study, you will be asked to do the following:
 Complete a screening form to see if you qualify for the study. You are invited to
participate if you are a healthy adult with no history of colon diseases,
diverticulosis/diverticulitis, no chronic diarrhea or constipation, and have not been on
antibiotics in the last 6 weeks. If you are a women you must be premenopausal and
not pregnant or breastfeeding.
 Prior to starting the study (week 0), you will be asked to fill out a 3 day diet diary on 3
consecutive days to give us an idea of your normal diet.
 Weeks 1-3 is the first feeding period, you will consume ½ cup portion of ice cream
daily. The ice cream will either be plain vanilla, made using the UNL dairy store recipe,
or this same ice cream with two types of helpful bacteria (like those found in yogurt),
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Lactobacillus casei and Bifido bacterium bifido, and one prebiotic, inulin (a type of
fiber) added. Each day you will fill out a brief log book evaluating your stool and gas
levels as well as tracking how much ice cream you consumed.
At the end of each week of the study (days 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77,
84) you will be asked to provide a stool sample (at least 1 gram is needed). This
sample will need to be collected by you then either brought directly to campus or kept
chilled or frozen until it can be dropped off in the provided coolers. By using the
coolers, you do not have to bring the samples immediately to campus but can bring
them at a time that works best for you. An email reminder to collect each sample and
schedule a drop off time will be sent to you or you can email the primary investigator.
All needed equipment will be provided, including stool sample collectors, gloves, and
coolers.
Weeks 4-6 is the first washout period. You will be asked to follow your normal diet and
collect stool samples on each day for the first 3 days (days 22, 23, 24) of week 4 as
well as the above mentioned weekly samples. These samples are needed because
often the most rapid change in number of the helpful bacteria occurs at this time.
Weeks 7-9 is the second feeding period and you will do the same process as
described for weeks 1-3.
Weeks 10-12 is the second washout period. The steps will be the same as week 4-6
with samples collected on the first 3 days (days 64, 65, 66).
Email reminders will be sent throughout the study to remind you to collect stool
samples, schedule drop off times, and to schedule times for you to pick up your ice
cream. The meeting points will either be Ruth Leverton Hall room 115 or 312.
Not everyone has a bowel movement every day. If there is a day that you cannot
provide a sample you can still continue your participation in the study. If this becomes
a frequent issue, you may want to discuss discontinuing participation with the primary
investigator. Also, be aware that each sample you miss will decrease your
compensation received at the end of the study.

Benefits:
There are no direct benefits to participants. They are contributing to furthering scientific
research which could benefit society through the development of a product that may
promote gut health improvements.
Risks and/or Discomforts:
Participants may experience some discomfort due to gas, bloating, constipation, or
diarrhea as a side effect but this usually goes away in a few days and is the normal
reaction of the body to increasing fiber intake. If any problems arise you should seek
medical care at your medical care provider at your own expense.
Confidentiality:
Any information obtained during this study which could identify you will be kept strictly
confidential. . Documents linking your name to your assigned numeric code will be
destroyed after all data has been collected and verified. The other paper data (all those
with just your numeric code) will be stored in a locked cabinet in LEV 312 and will only
be seen by the investigators during the study and will be stored for the required 3 years
All stool samples will be stored in LEV 114 or ASCI C120 using the numerical code you
will be assigned and disposed of after analysis. The information obtained in this study
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may be published in scientific journals or presented at scientific meetings but the data
will be reported as aggregated data.
Compensation:
You will receive a $25 Walmart gift card for participating in this project and an additional
$5 gift card amount for each stool sample provided. This compensation will be given as
a lump sum upon completion or termination of participation in the study. If all stool
samples are provided, you will receive a Wal-Mart gift card of $120. This final total will
decrease by $5 for each stool sample that was not provided. For amounts greater than
$50, your Social Security Number will need to be provided. A copy of this receipt will be
kept for our records, and you will be given one copy.
Opportunity to Ask Questions:
As mentioned in the introduction, you may ask any questions concerning this research
and have those questions answered before agreeing to participate in or during the study.
Or you may contact the investigator at the phone number or email above. Please contact
the University of Nebraska-Lincoln Institutional Review Board at (402) 472-6965 to voice
concerns about the research or if you have any questions about your rights as a
research participant.
Freedom to Withdraw:
Participation in this study is voluntary. You can refuse to participate or withdraw at any
time without harming your relationship with the researchers or the University of
Nebraska-Lincoln, or in any other way receive a penalty or loss of benefits to which you
are otherwise entitled.
Consent, Right to Receive a Copy:
You are voluntarily making a decision whether or not to participate in this research study.
Your signature certifies that you have decided to participate having read and understood
the information presented. You will be given a copy of this consent form to keep.
Signature of Participant:
______________________________________
Signature of Research Participant

___________________________
Date

Participant’s email: _______________________________________
Signature of Principal Investigators:
_______________________________________________________
Erin McNamara, BS, RD
Date
_______________________________________________________
Julie A. Albrecht, PhD, RD
Date
110 Ruth Leverton Hall / P.O. Box 830806 / Lincoln, NE 68583-0806 / (402) 472-3716 / Fax (402) 472-1587

Appendix 6. Food Frequency Form

Probiotics

less than 1 Once a
a week
week

2-3x a
week

4-6x a
week

once a
day

2+ a
day

less than 1 Once a
a week
week

2-3x a
week

4-6x a
week

once a
day

2+ a
day

Kefir
Yogurt
Milk with added live cultures
Buttermilk
Smoothies, butter, and sour cream which are labeled "cultured"
Fermented foods like saurkraut, kimchi, or tempeh
Miso
Microalgae ex/spriulina, green algae
Probiotic supplements (pills, powder, etc.)
Prebiotic
How often do you eat any fruit fresh or canned (not counting juice?)
Fruit juice like orange, apple, grape; fresh, frozen, or canned. (not sodas or
other drinks?
Vegetable juice, like tomato juice, V-8, carrot
Green salad
Potatoes, any kind, including baked, mashed, or french fried
Vegetable soup, or stew with vegetables
Any other vegetables, including green beans, peas, corn, brocooli, or any
other kind
Fiber cereals like raisin bran, shredded wheat or Fruit-n-Fiber
Beans such as baked beans, pinto, kidney, or lentils (not green beans)
bread such as whole wheat, white whole wheat or rye
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Appendix 7. Daily log book page
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Appendix 8.
Weekly schedule for study with fecal collection days highlighted in blue.
Phase
Day of Study
Prefeeding
0
1 2 3 4 5 6 7
8 9 10 11 12 13 14
Feeding
15 16 17 18 19 20 21
22 23 24 25 26 27 28
Washout 29 30 31 32 33 34 35
36 37 38 39 40 41 42
43 44 45 46 47 48 49
50 51 52 53 54 55 56
Feeding
57 58 59 60 61 62 63
64 65 66 67 68 69 70
Washout 71 72 73 74 75 76 77
78 79 80 81 82 83 84
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Appendix 9. USDA supertracker example section from multi-day report

Nutrients Report
Your plan is based on a default 2000 Calorie allowance.
Nutrients

Target

Average Eaten

Status

Total Calories

2000 Calories

1712 Calories

OK

Protein (g)***

46 g

79 g

OK

Protein (% Calories)***

10 - 35% Calories

19% Calories

OK

Carbohydrate (g)***

130 g

228 g

OK

Carbohydrate (%
Calories)***
Dietary Fiber

45 - 65% Calories

53% Calories

OK

25 g

24 g

Under

Total Sugars

No Daily Target or Limit

64 g

No Daily Target
or Limit

Added Sugars

No Daily Target or Limit

15 g

No Daily Target
or Limit

Total Fat

20 - 35% Calories

30% Calories

OK

Saturated Fat

< 10% Calories

7% Calories

OK

Polyunsaturated Fat

No Daily Target or Limit

7% Calories

No Daily Target
or Limit

Monounsaturated Fat

No Daily Target or Limit

13% Calories

No Daily Target
or Limit

Linoleic Acid (g)***

12 g

12 g

OK

Linoleic Acid (%
Calories)***

5 - 10% Calories

6% Calories

OK

α-Linolenic Acid (%
Calories)***

0.6 - 1.2% Calories

0.3% Calories

Under

α-Linolenic Acid (g)***

1.1 g

0.6 g

Under

Omega 3 - EPA

No Daily Target or Limit

9 mg

No Daily Target
or Limit

Omega 3 - DHA

No Daily Target or Limit

34 mg

No Daily Target
or Limit

Cholesterol

< 300 mg

171 mg

OK
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Appendix 10. example page section from daily SuperTracker
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Appendix 11
Sequences for primers used:
Forward: 5’-GAG TGT ACC TTT CGA ATA AGC-3’
Reverse: 5’-CCC TTT ACG AAT AAA TC-3’
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Appendix 12 dissociation curve results for 16s set 1 example image with boxed part
being one of the samples that was thrown out for inaccuracy.

